Pre-CART baseline characteristics and post-CART outcomes
| . | Bridging RT . | Total (N = 150) . | P value . | |
|---|---|---|---|---|
| No (n = 102) . | Yes (n = 48) . | |||
| Pre-CART baseline characteristics | ||||
| Age, median (range), y | 56 (18-82) | 60 (19-84) | 57 (18-84) | .324 |
| Sex | ||||
| F | 30 (29.4%) | 22 (45.8%) | 52 (34.7%) | .049 |
| M | 72 (70.6%) | 26 (54.2%) | 98 (65.3%) | |
| Histology | ||||
| DLBCL | 79 (77.5%) | 30 (62.5%) | 109 (72.7%) | .15 |
| FL | 8 (7.8%) | 3 (6.3%) | 11 (7.3%) | |
| GZL | 2 (2%) | 0 (0%) | 2 (1.3%) | |
| HGBCL | 8 (7.8%) | 9 (18.8%) | 17 (11.3%) | |
| MCL | 3 (2.9%) | 4 (8.3%) | 7 (4.7%) | |
| PMBCL | 2 (2%) | 2 (4.2%) | 4 (2.7%) | |
| CART product | ||||
| Axicabtagene ciloleucel | 92 (90.2%) | 39 (81.3%) | 131 (87.3%) | .62 |
| Tisagenlecleucel | 5 (4.9%) | 3 (6.2%) | 8 (5.3%) | |
| Brexucabtagene autoleucel | 3 (2.9%) | 4 (8.3%) | 7 (4.7%) | |
| Lisocabtagene maraleucel | 2 (2.0%) | 2 (4.2%) | 4 (2.7%) | |
| No. of previous lines of therapy, median (range) | 2 (1-7) | 2 (1-4) | 2 (1-7) | .684 |
| Maximum tumor size, median (range), cm | 5.1 (0.9-22.4) | 6.85 (1.7-21) | 6 (0.9-22.4) | .181 |
| Highest SUVmax, median (range) | 14.95 (2.7-44.1) | 17.45 (5-43.2) | 15.4 (2.7-44.1) | .324 |
| No. of disease sites pre-CART, median (range) | 2 (1-4) | 2 (1-4) | 2 (1-4) | .593 |
| Extranodal involvement | ||||
| No | 73 (71.6%) | 24 (50%) | 97 (64.7%) | .01 |
| Yes | 29 (28.4%) | 24 (50%) | 53 (35.3%) | |
| LDH level before leukapheresis, median (range) | 233 (96-1179) | 248 (144-892) | 239 (96-1179) | .72 |
| LDH level pre-CART, median (range) | 230 (10.2-1631) | 211 (144-1831) | 221 (10.2-1831) | .445 |
| CRP level before leukapheresis, median (range) | 5 (3-279.7) | 10.15 (3-114) | 7.5 (3-279.7) | .028 |
| CRP level pre-CART, median (range) | 16.1 (2.8-337.6) | 10.6 (3-191.7) | 14.5 (2.8-337.6) | .22 |
| Ferritin level before leukapheresis, median (range) | 247 (19-2577) | 290 (6-3710) | 261 (6-3710) | .65 |
| Ferritin level pre-CART, median (range) | 339.5 (4.8-7357) | 284.5 (34-3653) | 333.5 (4.8-7357) | .6 |
| Bridging systemic therapy | ||||
| No | 66 (64.7%) | 43 (89.6%) | 109 (72.7%) | .001 |
| Yes | 36 (35.3%) | 5 (10.4%) | 41 (27.3%) | |
| Post-CART outcomes | ||||
| CRS max grade 2+ | 41 (40.2%) | 20 (41.7%) | 61 (40.7%) | .864 |
| ICANS max grade 2+ | 35 (34.3%) | 10 (20.8%) | 45 (30%) | .093 |
| Objective response | 80 (78.4%) | 44 (91.7%) | 124 (82.7%) | .046 |
| CR | 55 (53.9%) | 30 (62.5%) | 85 (56.7%) | .323 |
| Partial response | 25 (24.5%) | 14 (29.2%) | 39 (26.0%) | .544 |
| Sustained CR | 34 (33%) | 26 (54%) | 60 (40%) | .015 |
| Any progression/relapse | 57 (55.9%) | 16 (33.3%) | 73 (48.7%) | .01 |
| Local relapse involving pre-existing sites | 47 (46.1%) | 10 (20.8%) | 57 (38.0%) | .003 |
| Isolated local relapse in pre-existing sites only | 25 (24.5%) | 3 (6.3%) | 28 (18.7%) | .007 |
| Relapse/progression in both pre-existing and new sites | 22 (21.5%) | 7 (14.5%) | 29 (19.3%) | .312 |
| Isolated distant progression in new sites only | 10 (9.8%) | 6 (12.5%) | 16 (10.7%) | .618 |
| . | Bridging RT . | Total (N = 150) . | P value . | |
|---|---|---|---|---|
| No (n = 102) . | Yes (n = 48) . | |||
| Pre-CART baseline characteristics | ||||
| Age, median (range), y | 56 (18-82) | 60 (19-84) | 57 (18-84) | .324 |
| Sex | ||||
| F | 30 (29.4%) | 22 (45.8%) | 52 (34.7%) | .049 |
| M | 72 (70.6%) | 26 (54.2%) | 98 (65.3%) | |
| Histology | ||||
| DLBCL | 79 (77.5%) | 30 (62.5%) | 109 (72.7%) | .15 |
| FL | 8 (7.8%) | 3 (6.3%) | 11 (7.3%) | |
| GZL | 2 (2%) | 0 (0%) | 2 (1.3%) | |
| HGBCL | 8 (7.8%) | 9 (18.8%) | 17 (11.3%) | |
| MCL | 3 (2.9%) | 4 (8.3%) | 7 (4.7%) | |
| PMBCL | 2 (2%) | 2 (4.2%) | 4 (2.7%) | |
| CART product | ||||
| Axicabtagene ciloleucel | 92 (90.2%) | 39 (81.3%) | 131 (87.3%) | .62 |
| Tisagenlecleucel | 5 (4.9%) | 3 (6.2%) | 8 (5.3%) | |
| Brexucabtagene autoleucel | 3 (2.9%) | 4 (8.3%) | 7 (4.7%) | |
| Lisocabtagene maraleucel | 2 (2.0%) | 2 (4.2%) | 4 (2.7%) | |
| No. of previous lines of therapy, median (range) | 2 (1-7) | 2 (1-4) | 2 (1-7) | .684 |
| Maximum tumor size, median (range), cm | 5.1 (0.9-22.4) | 6.85 (1.7-21) | 6 (0.9-22.4) | .181 |
| Highest SUVmax, median (range) | 14.95 (2.7-44.1) | 17.45 (5-43.2) | 15.4 (2.7-44.1) | .324 |
| No. of disease sites pre-CART, median (range) | 2 (1-4) | 2 (1-4) | 2 (1-4) | .593 |
| Extranodal involvement | ||||
| No | 73 (71.6%) | 24 (50%) | 97 (64.7%) | .01 |
| Yes | 29 (28.4%) | 24 (50%) | 53 (35.3%) | |
| LDH level before leukapheresis, median (range) | 233 (96-1179) | 248 (144-892) | 239 (96-1179) | .72 |
| LDH level pre-CART, median (range) | 230 (10.2-1631) | 211 (144-1831) | 221 (10.2-1831) | .445 |
| CRP level before leukapheresis, median (range) | 5 (3-279.7) | 10.15 (3-114) | 7.5 (3-279.7) | .028 |
| CRP level pre-CART, median (range) | 16.1 (2.8-337.6) | 10.6 (3-191.7) | 14.5 (2.8-337.6) | .22 |
| Ferritin level before leukapheresis, median (range) | 247 (19-2577) | 290 (6-3710) | 261 (6-3710) | .65 |
| Ferritin level pre-CART, median (range) | 339.5 (4.8-7357) | 284.5 (34-3653) | 333.5 (4.8-7357) | .6 |
| Bridging systemic therapy | ||||
| No | 66 (64.7%) | 43 (89.6%) | 109 (72.7%) | .001 |
| Yes | 36 (35.3%) | 5 (10.4%) | 41 (27.3%) | |
| Post-CART outcomes | ||||
| CRS max grade 2+ | 41 (40.2%) | 20 (41.7%) | 61 (40.7%) | .864 |
| ICANS max grade 2+ | 35 (34.3%) | 10 (20.8%) | 45 (30%) | .093 |
| Objective response | 80 (78.4%) | 44 (91.7%) | 124 (82.7%) | .046 |
| CR | 55 (53.9%) | 30 (62.5%) | 85 (56.7%) | .323 |
| Partial response | 25 (24.5%) | 14 (29.2%) | 39 (26.0%) | .544 |
| Sustained CR | 34 (33%) | 26 (54%) | 60 (40%) | .015 |
| Any progression/relapse | 57 (55.9%) | 16 (33.3%) | 73 (48.7%) | .01 |
| Local relapse involving pre-existing sites | 47 (46.1%) | 10 (20.8%) | 57 (38.0%) | .003 |
| Isolated local relapse in pre-existing sites only | 25 (24.5%) | 3 (6.3%) | 28 (18.7%) | .007 |
| Relapse/progression in both pre-existing and new sites | 22 (21.5%) | 7 (14.5%) | 29 (19.3%) | .312 |
| Isolated distant progression in new sites only | 10 (9.8%) | 6 (12.5%) | 16 (10.7%) | .618 |
DLBCL, diffuse large B-cell lymphoma; F, female; FL, follicular lymphoma; GZL, gray zone lymphoma; HGBCL, high grade B-cell lymphoma; M, male; MCL, mantle cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; LDH, lactate dehydrogenase.
Boldface indicates statistical significance.